IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Addressed to:

Applicant(s): Ono et al.

Confirmation No.: Unassigned

Commissioner for Patents

Serial No.: Unassigned

Group Art Unit:

Unassigned

P.O. Box 1450

Alexandria, VA 22313-1450

Filed:

June 22, 2006

Examiner:

Unassigned

Title: METHOD OF DETECTING THROMBOSIS BY MEASURING VON

WILLENBRAND FACTOR-CLEAVING PROTEASE

INFORMATION DISCLOSURE STATEMENT

Dea	r Sir:							
Thi	s Information Disclosure Statement is being:							
\boxtimes	submitted together with the application being filed herein; or							
	submitted for the first time; or							
	submitted as a Supplemental Information Disclosure Statement in addition to an Information Disclosure Statement, which was filed on; or							
	filed together with the application on, and such submission is being made:							
	under 37 CFR 1.97(b), within three months of filing national application or date of entry of international application, or before mailing date of first office action on the merits, whichever occurs last; or							
	under 37 CFR 1.97(c) together with either a:							
	Statement under 37 CFR 1.97(e); or							
	\$180.00 fee under 37 CFR 1.17(p), after the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first; or							
	under 37 CFR 1.97(d), filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee, together with a:							
	Statement under 37 CFR 1.97(e); and							
	\$180.00 fee under 37 CFR 1.17(p);							
\boxtimes	and, furthermore, please note that this Information Disclosure Statement is being submitted: ☑ to disclose references cited in the Search Report in a related foreign application; and ☐ within 30 days of receipt of the Search Report (see 37 CFR 1.704(d)).							
	Comment(s):							

Applicant(s) submit herewith an Information Disclosure Citation form listing patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application, and for which there may be a duty to disclose in accordance with 37 CFR 1.56, together with any required copies of the listed references.

It is requested that the information disclosed herein be made of record in this application.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date of Deposit: June 22, 2006

Erika J. Senska,

Respectfully submitted,

Erika Jenska, Esq.

Attorney for Applicant(s) Registration No. 53,312

Dated: June 22, 2006

HESLIN ROTHENBERG FARLEY & MESITI P.C.

5 Columbia Circle

Albany, New York 12203

Telephone: (518) 452-5600

Facsimile: (518) 452-5579

INFORMATION	DISCLOSURE	CITATION
-------------	------------	----------

1AP2 Rec'd PCT/PTO 22 JUN 2006

Seria 1.0 Unas 8 He 4 25 Docket No 2352.014 Examiner: Unassigned Applicant(s):. Ono et al.

				Fi	ling Date: June 22	, 2006		GAL) : L	Inassig	gned_	
,		·		U.S. PAT	ENT DOCUMENTS		Υ		 			
Examiner Initial	Ref		ocument Number	Date	Name		Cla	ss	Subclass		Filing D If Approp	
							<u> </u>			 		
		1					<u> </u>			+	· 	
				U.S. PATENT AP	PLICATION PUBLIC	ATIONS	<u> </u>					
Examiner Initial	Ref		Document Number	Date	Name		Class		Subclass		Filing Da	
	ļ											
											<u></u>	
				FOREIGN	PATENT DOCUMENT	rs						
Examiner Initial	Ref	Doc	ument Number	Date	Country	Cla	ss	Subclass		Tran	slation	Abstrac
Till Car											No	Yes
	CA	JP 4-02	29931	23.05.1990	Japan							×
	СВ	WO 03	3/16492 A	24.02.2003	Japan							ļ
:-						ļ						-
				OTH	IER DOCUMENTS	<u> </u>					<u></u>	<u></u>
					, title, Date, Pertinent Pa	iges. etc.)						
		DA	Furlan, M., e Cleaving vor pp. 4223-423	et al., "Partial Pur n Willebrand Fac	ification and Char tor to Fragments P	acteriza	tion of a	a Prot Vivo	ease Fro	m Hur sis", B	man Pla Blood, V	asma /ol. 87,
		DB	Gerritsen, H., "Partial Amino acid sequence of purified von Willebrand factor-cleaving protease", Blood, Vol. 98, pp. 1654-1661 (2001).									
	_	DC	Fujikawa, K. identification (2001).	., et al., Purificati n as a new memb	on of human von V er of the metallopr	Willebra oteinase	and fact e family	or-cle	aving prood, Vol	otease . 98, p	an its	2-1666
		DD			f von Willebrand i hrombotic thrombo							al

Chem., Vol. 276, pp. 41059-41063 (2001).

10/584425 IAP2 Rec'd PCT/PTO 22 JUN 2006 Synthesized in the Lines

	DE	Soejima, K., et al., "A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor-Cleaving Protease?" The Jrnl. of Biological Chem., Vol. 130, pp. 475-480 (2001).
	DF	Levy, C.G., et al., "Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura", Nature, United Kingdom, Vol. 413, pp. 488-494 (2001).
	DG	Kokame, K., et al., "VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13", Blood, Vol. 103, pp. 607-612, (2004).
EXAMINER:		Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.